DNA bar coding and pyrosequencing to analyze adverse events in therapeutic gene transfer
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Gene transfer has been used to correct inherited immunodeficiencies, but in several patients integration of therapeutic retroviral vectors activated proto-oncogenes and caused leukemia. Here, we describe improved methods for characterizing integration site populations from gene transfer studies using DNA bar coding and pyrosequencing. We characterized 160,232 integration site sequences in 28 tissue samples from eight mice, where Rag1 or Artemis deficiencies were corrected by introducing the missing gene with gamma-retroviral or lentiviral vectors. The integration sites were characterized for their genomic distributions, including proximity to proto-oncogenes. Several mice harbored abnormal lymphoproliferations following therapy--in these cases, comparison of the location and frequency of isolation of integration sites across multiple tissues helped clarify the contribution of specific proviruses to the adverse events. We also took advantage of the large number of pyrosequencing reads to show that recovery of integration sites can be highly biased by the use of restriction enzyme cleavage of genomic DNA, which is a limitation in all widely used methods, but describe improved approaches that take advantage of the power of pyrosequencing to overcome this problem. The methods described here should allow integration site populations from human gene therapy to be deeply characterized with spatial and temporal resolution.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
LMO2 -Associated Clonal T Cell Proliferation in Two Patients after Gene Therapy for SCID-X1
Hacein-Bey-Abina, S., Von Kalle, C., Schmidt, M., McCormack, M. P., Wulffraat, N., Leboulch, P., Lim, A., Osborne, C. S., Pawliuk, R., Morillon, E., et al. (2003) · Science · doi:10.1126/science.1088547 · Cited by 3,587
Self-citationA census of human cancer genes
Futreal, P. A., Coin, L., Marshall, M., Down, T., Hubbard, T., Wooster, R., Rahman, N., & Stratton, M. R. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1299 · Cited by 3,184
A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency
Hacein-Bey-Abina, S., von Kalle, C., Schmidt, M., Le Deist, F., Wulffraat, N., McIntyre, E., Radford, I., Villeval, J.-L., Fraser, C. C., Cavazzana-Calvo, M., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejm200301163480314 · Cited by 1,867 · cited 2×
“Lentiviral (PGK) vector in artemis-deficient mice 401 Healthy control LN 1647 (65) 117 (4) 7.”
BackgroundSelf-citationInsertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1
Hacein-Bey-Abina, S., Garrigue, A., Wang, G. P., Soulier, J., Lim, A., Morillon, E., Clappier, E., Caccavelli, L., Delabesse, E., Beldjord, K., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci35700 · Cited by 1,854
Self-citationHIV-1 Integration in the Human Genome Favors Active Genes and Local Hotspots
Schröder, A. R. W., Shinn, P., Chen, H., Berry, C., Ecker, J. R., & Bushman, F. (2002) · Cell · doi:10.1016/s0092-8674(02)00864-4 · Cited by 1,832
Self-citationTranscription Start Regions in the Human Genome Are Favored Targets for MLV Integration
Wu, X., Li, Y., Crise, B., & Burgess, S. M. (2003) · Science · doi:10.1126/science.1083413 · Cited by 1,305 · cited 3×
“4) Lymphoproliferation LN 3687 (215) 89 (20) 2.”
MethodResultA role for LEDGF/p75 in targeting HIV DNA integration
Ciuffi, A., Llano, M., Poeschla, E., Hoffmann, C., Leipzig, J., Shinn, P., Ecker, J. R., & Bushman, F. (2005) · Nature Medicine · doi:10.1038/nm1329 · Cited by 658 · cited 1×
“The lentiviral vector was prepared as described previously (17,18).”
MethodSelf-citationWang, G. P., Ciuffi, A., Leipzig, J., Berry, C. C., & Bushman, F. D. (2007) · Genome Research · doi:10.1101/gr.6286907 · Cited by 457 · cited 4×
“Detailed bioinformatic methods can be found in (26) and (18), and Supplementary Data 1–4.”
MethodInfluentialSelf-citationRetroviral DNA integration: viral and cellular determinants of target-site selection
Lewinski, M. K., Yamashita, M., Emerman, M., Ciuffi, A., Marshall, H., Crawford, G., Collins, F., Shinn, P., Leipzig, J., Hannenhalli, S., et al. (2006) · PLoS Pathogens · doi:10.1371/journal.ppat.0020060 · Cited by 364
Self-citationTurlure, F. (2006) · Nucleic Acids Research · doi:10.1093/nar/gkl052 · Cited by 181 · cited 1×
“2) 613 Healthy cells pretransplantation Sca1+ 26477 (37) 0 (0) 0 (0) 0 (0) Lymphoproliferation LN 42 (5) 0 (0) 0 (0) 1.”
Cited by
Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1
Hacein-Bey-Abina, S., Garrigue, A., Wang, G. P., Soulier, J., Lim, A., Morillon, E., Clappier, E., Caccavelli, L., Delabesse, E., Beldjord, K., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci35700 · Cited by 1,854
“tion of restriction enzyme cleavage site in the human genome (49).”
BackgroundSelf-citationTransfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia
Cavazzana-Calvo, M., Payen, E., Negre, O., Wang, G., Hehir, K., Fusil, F., Down, J., Denaro, M., Brady, T., Westerman, K., et al. (2010) · Nature · doi:10.1038/nature09328 · Cited by 1,276
Self-citationSingle-cell dissection of transcriptional heterogeneity in human colon tumors
Dalerba, P., Kalisky, T., Sahoo, D., Rajendran, P. S., Rothenberg, M. E., Leyrat, A. A., Sim, S., Okamoto, J., Johnston, D. M., Qian, D., et al. (2011) · Nature Biotechnology · doi:10.1038/nbt.2038 · Cited by 703
Decade-Long Safety and Function of Retroviral-Modified Chimeric Antigen Receptor T Cells
Scholler, J., Brady, T. L., Binder-Scholl, G., Hwang, W.-T., Plesa, G., Hege, K. M., Vogel, A. N., Kalos, M., Riley, J. L., Deeks, S. G., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003761 · Cited by 652
Self-citationClonal analysis of lineage fate in native haematopoiesis
Rodriguez-Fraticelli, A. E., Wolock, S. L., Weinreb, C. S., Panero, R., Patel, S. H., Jankovic, M., Sun, J., Calogero, R. A., Klein, A. M., & Camargo, F. D. (2018) · Nature · doi:10.1038/nature25168 · Cited by 596
“Others and we have observed significant tag amplification biases with this method, which limit the quantitative potential of the clonal data obtained 11,32,33 .”
Zhang, C., Liu, J., Zhong, J. F., & Zhang, X. (2017) · Biomarker Research · doi:10.1186/s40364-017-0102-y · Cited by 578
“The insertion mutation used to induce the immune reaction can lead to tumorigenesis and toxicity, the carrier capacity is limited and the titer achieved is not high enough [33, 34].”
Modlich, U., Navarro, S., Zychlinski, D., Maetzig, T., Knoess, S., Brugman, M. H., Schambach, A., Charrier, S., Galy, A., Thrasher, A. J., et al. (2009) · Molecular Therapy · doi:10.1038/mt.2009.179 · Cited by 387
Ex vivo gene transfer and correction for cell-based therapies
Naldini, L. (2011) · Nature Reviews Genetics · doi:10.1038/nrg2985 · Cited by 358
Outcomes Following Gene Therapy in Patients With Severe Wiskott-Aldrich Syndrome
Hacein-Bey Abina, S., Gaspar, H. B., Blondeau, J., Caccavelli, L., Charrier, S., Buckland, K., Picard, C., Six, E., Himoudi, N., Gilmour, K., et al. (2015) · JAMA · doi:10.1001/jama.2015.3253 · Cited by 357
Self-citationHIV Integration Targeting: A Pathway Involving Transportin-3 and the Nuclear Pore Protein RanBP2
Ocwieja, K. E., Brady, T. L., Ronen, K., Huegel, A., Roth, S. L., Schaller, T., James, L. C., Towers, G. J., Young, J. A. T., Chanda, S. K., et al. (2011) · PLoS Pathogens · doi:10.1371/journal.ppat.1001313 · Cited by 212
Self-citationGenome-wide high-throughput integrome analyses by nrLAM-PCR and next-generation sequencing
Paruzynski, A., Arens, A., Gabriel, R., Bartholomae, C. C., Scholz, S., Wang, W., Wolf, S., Glimm, H., Schmidt, M., & von Kalle, C. (2010) · Nature Protocols · doi:10.1038/nprot.2010.87 · Cited by 175
“to integration site analyses, we and others have achieved a marked increase in the retrieval of integration site information with the goal of determining the clonal repertoire present in analyzed sample”
BackgroundStem cell gene therapy: the risks of insertional mutagenesis and approaches to minimize genotoxicity
Wu, C., & Dunbar, C. E. (2011) · Frontiers of Medicine · doi:10.1007/s11684-011-0159-1 · Cited by 114
“The power of any IS retrieval methodology has been greatly increased by replacing shotgun cloning and then sequencing of inverse PCR or LAM-PCR products with high throughput direct sequencing methodologies such as 454 pyrosequencing [40], Instead of at most hundreds of IS being able to be isolated and identified by an…”
MethodRetroviral integration site selection
Desfarges, S., & Ciuffi, A. (2010) · Viruses · doi:10.3390/v2010111 · Cited by 78
“However, not all retroviruses display the same genotoxic potential, as gammaretroviruses for example appeared to be more prone to insertional mutagenesis than lentiviruses [33-37].”
BackgroundSelf-citation
Metadata
- Authors
- Wang, G. P., Garrigue, A., Ciuffi, A., Ronen, K., Leipzig, J., Berry, C., Lagresle-Peyrou, C., Benjelloun, F., Hacein-Bey-Abina, S., Fischer, A., Cavazzana-Calvo, M., & Bushman, F. D.
- Venue
- Nucleic Acids Research
- Publisher
- Oxford University Press (OUP)
- Published
- 2008-04-14
- Volume
- 36
- Issue
- 9
- Pages
- e49-e49
- ISSN
- 0305-1048 (ISSN-L)
- 1362-4962
- OpenAlex
- W2111521836
- Cited by
- 100
- References
- 11
- FWCI
- 8.61
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.